MINISTRY OF HEALTH MALAYSIA

GUIDELINE FOR REGISTRATION OF DRUG-MEDICAL DEVICE AND MEDICAL DEVICE-DRUG COMBINATION PRODUCTS

Second Edition – 20th June 2019

Portal: www.moh.gov.my
Email: kkm@moh.gov.my

Medical Device Authority
Ministry of Health Malaysia

PREAMBLE

- This present guideline serves as a guidance for the submission of registration application of drug-medical device/ medical device-drug combination products, and change/variation application.

- Drug-medical device/ medical device-drug combination products are regulated according to the classification whether as drug or medical device based on the primary mode of action (PMOA).

- Combination products regulated as drug by Drug Control Authority is in accordance with the requirements set forth in the Control of Drugs and Cosmetics Regulations 1984 which is promulgated under Sale of Drug Act 1952 and any other relevant documents published by NPRA.

- Combination products regulated as medical device by Medical Device Authority is in accordance with the requirements set forth in the Medical Device Act 2012 (Act 737) and its subsidiary legislations, and any other relevant documents published by MDA.

- Any drug substances used as ancillary to medical device which is listed as a scheduled poison shall be regulated in accordance with the Poison Act 1952.

- The written laws shall take precedence over this guidance document in any event of discrepancy.

- The scope of this guideline includes information relating to dossier requirements, procedures for submission of combination products registration and change/variation application.

- Applicants shall familiarize with the contents of this guidance document and the governing legislations before they submit registration applications.

- The Authority may request for information or specify conditions not described in this document that is deemed necessary to ensure the safety, quality, efficacy and performance of the combination product.

- The Authority reserves the right to amend any part of this guideline whenever it deems fit.

- This guidance shall be fully enforced on 1st July 2019.

- Any enquiry on registration, or change/variation application of combination product may be submitted to the relevant agency:

1. Secretary,
   Drug Control Authority,
   National Pharmaceutical Regulatory Agency,
   Ministry of Health Malaysia,
   Lot 36, Jalan Universiti,
   46200 Petaling Jaya, Selangor.
   Tel : +603-78835400 Fax :03-7956 2924
   E-mail : helpdesk@npra.gov.my
   Portal : http://npra.moh.gov.my/

2. Chief Executive
   Medical Device Authority (MDA),
   Ministry of Health Malaysia,
   Level 6, Prima 9, Prima Avenue II,
   Blok 3547, Persiaran APEC,
   63000 Cyberjaya, Selangor
   Tel : +603-8230 0300 Fax : +603-8230 0200
   E-mail : combination.product@mda.gov.my
   Portal : http://www.mda.gov.my

GLOSSARY

Agency:

Refers to National Pharmaceutical Regulatory Agency (NPRA) or Medical Device Authority (MDA)

Ancillary Dossier:

Dossier required by the secondary agency

Drug-Medical Device Combination Product (DMDCP):

Primary mode of action is based on pharmacological, immunological or metabolic action in/on the body where NPRA is the primary agency of the combination product

Medical Device-Drug Combination Product (MDDCP):

Primary mode of action in or on the human body is not based on pharmacological, immunological or metabolic means, but that may be assisted in its intended function by such means where MDA is the primary agency of the combination product

Primary Agency:

Agency with primary regulatory responsibility for a combination product which is determined by the primary mode of action of the product

Primary Dossier:

Dossier required by the primary agency

Primary Mode of Action:

Mode of action that provides the greatest contribution to the overall therapeutic effects of the combination product

Secondary Agency:

Agency that regulate the other part(s) included in the combination product

ABBREVIATIONS AND ACRONYMS

CAB	Conformity Assessment Body
CDCR	Control of Drugs & Cosmetics Regulations 1984
COA	Certificate of Analysis
CSDT	Common Submission Dossier Template
DCA	Drug Control Authority
DRGD	Drug Registration Guidance Document
GMP	Good Manufacturing Practice
MDA	Medical Device Authority
NPRA	National Pharmaceutical Regulatory Agency

CONTENTS

1.0 INTRODUCTION

1.1 DEFINITION OF MEDICAL DEVICE

The term medical device includes:

a. any instrument, apparatus, implement, machine, appliance, implant, in-vitro reagent or calibrator, software, material or other similar or related article intended by the manufacturer to be used alone or in combination, for human beings for the purpose of—

   i. diagnosis, prevention, monitoring, treatment or alleviation of disease;
   ii. diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
   iii. investigation, replacement or modification, or support of the anatomy or of a physiological process;
   iv. support or sustaining life;
   v. control of conception;
   vi. disinfection of medical device; or
   vii. providing information for medical or diagnostic purpose by means of in-vitro examination of specimens derived from the human body, which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but that may be assisted in its intended function by such means; and

b. any instrument, apparatus, implement, machine, appliance, implant, in-vitro reagent or calibrator, software, material or other similar or related article, to be used on the human body, which the Minister may, after taking into consideration issues of public safety, public health or public risk, declare to be a medical device by order published in the Gazette

1.2 DEFINITION OF DRUG

Under the CDCR 1984, Regulation 2: "*Product*" means:

a. a drug[1] in a dosage unit or otherwise, for use wholly or mainly by being administered to one or more human beings or animals for a medicinal purpose[2]; or
b. a drug[1] to be used as an ingredient of a preparation for a medicinal purpose[2].

Under Sales of Drug Act 1952, Section 2:

1. "***drug***" includes any substance, product or article intended to be used or capable, or purported or claimed to be capable, of being used on humans or any animal, whether internally or externally, for a medicinal purpose.
2. "***medicinal purpose***" means any of the following purposes:
    a. alleviating, treating, curing or preventing a disease or a pathological condition or symptoms of a disease;
    b. diagnosing a disease or ascertaining the existence, degree or extent of a physiological or pathological condition;
    c. contraception;
    d. inducing anaesthesia;
    e. maintaining, modifying, preventing, restoring, or interfering with, the normal operation of a physiological function;
    f. controlling body weight;
    g. general maintenance or promotion of health or well being

1.3 DEFINITION OF COMBINATION PRODUCT

The term combination product includes:

i. A product comprised of two or more regulated components, i.e., drug/device, biological/device, or drug/device/biological, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; OR
ii. Two or more separate products packaged together (co-packaged) in a single package or as a unit and comprised of drug and device products, device and biological products.

Products that are excluded from the term combination product and will be regulated separately:

i. A drug, device, or biological product packaged separately that according to its investigational plan or proposed labelling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product labelling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or
ii. Any investigational drug or device packaged separately that according to its proposed labelling is use only with another individually specified investigational drug,

device, or cosmetic product where both are required to achieve the intended use, indication or effect.

iii. Convenience pack product (example: first aid kit consists of medical device and non-scheduled poison product)

Refer Table III: Medical Device-Drug-Cosmetic Interphase (MDDCI) Product Classification Decision in Drug Registration Guidance Document (DRGD) or MDA's website for examples of Drug-Medical Device/Medical Device-Drug Combination Product classification.

Prior to registration, an applicant may apply classification application to NPRA through product classification form (NPRA 300.1) which is available at http://npra.moh.gov.my.

2.0 REGISTRATION PROCESS OF COMBINATION PRODUCT

The primary agency for registration of combination product is based on the primary mode of action/the principal mechanism of action by which the claimed effect or purpose of the product is achieved:

i. Drug is based on pharmacological, immunological or metabolic action in/on the body; shall be regulated by NPRA;

ii. Medical device does not achieve its primary mode of action in or on the human body by pharmacological, immunological or metabolic means, but that may be assisted in its intended function by such means; shall be regulated by MDA.

Flow of registration process of combination product is illustrated in **Figure 1**.



Figure 1: Flow of Registration Process of Combination Product

Explanatory Notes :

i. Applicant may submit application for endorsement letter and registration of combination product concurrently to both secondary and primary agency. However, the approval of combination product registration is subject to primary agency based on the fulfilment of registration requirements, as well as the receipt of endorsement letter from secondary agency.

ii. Refer **Appendix 5** for a thorough process flow pertaining evaluation of medical device component for a combination product.

iii. Stage 1 Drug-Medical Device Combination Product is NOT mandatory for:

a. low risk ancillary medical device components. They are not required to apply endorsement letter from MDA prior to their registration. Please refer Frequently Asked Questions (FAQs) on Drug-Medical Device Combination Products for the definition of low risk and medium/high risk medical device.
b. Ancillary medical device components that have already obtain registration approval with MDA through a medical device registration application with MDA. Proof of medical device registration certificate are required to be presented to NPRA when applying for Drug-Medical Device Combination Product registration.

2.1 DRUG-MEDICAL DEVICE COMBINATION PRODUCT REGISTRATION PROCESS (NPRA AS PRIMARY AGENCY)

The registration process of Drug-Medical Device combination product shall undergo the following 2 stages:

i. Stage 1 – Obtaining Endorsement from MDA
ii. Stage 2 – Application for Registration to NPRA

All the stages shall be completed, with the exception of low risk medical devices which may proceed directly to Stage 2- Application for Registration to NPRA.

Stage 1: Obtaining Endorsement from MDA

Applicant shall submit the following documents to MDA manually:

i. Application form for Endorsement Letter of Ancillary Component for Registration of Combination Product (Appendix 3: Form for Endorsement Letter of Ancillary Component for Registration of Combination Product)
ii. Ancillary Dossier (Appendix 1: Ancillary Medical Device Dossier Requirement for Drug- Medical Device Combination Product)

MDA shall issue an endorsement letter upon satisfactory review.

Stage 2: Application for Registration to NPRA

For the purpose of registration of Drug-Medical Device combination product, applicant shall submit an application for registration with the following documents to NPRA via the online QUEST system at http://npra.moh.gov.my:

i. Endorsement letter issued by MDA
ii. Data on drug in accordance to DRGD Section B: Product Registration Process

Recommendations from the evaluation on Drug-Medical Device combination product shall be presented to the Drug Evaluation Committee followed by the meeting of DCA for approval/rejection.
The Drug-Medical Device combination product shall be registered after the approval by the DCA.

Applicant shall refer to the product registration approval notification sent by the Authority or the Approved Product Registration List in NPRA website.

2.2 MEDICAL DEVICE-DRUG COMBINATION PRODUCT REGISTRATION PROCESS (MDA AS PRIMARY AGENCY)

The registration process of Medical Device-Drug combination product shall undergo the following 2 stages:

i. Stage 1 - Obtaining Endorsement from NPRA
ii. Stage 2 - Application for Registration to MDA

Stage 1: Obtaining Endorsement from NPRA

Applicant shall submit the following documents to NPRA manually:

i. Application Form for Endorsement Letter of Ancillary Component for Registration of Combination Product (Appendix 3: Form for Endorsement Letter of Ancillary Component for Registration of Combination Product)
ii. Ancillary Dossier (Appendix 2: Ancillary Drug Dossier Requirement for Medical Device-Drug Combination Product)

NPRA shall issue an endorsement letter upon satisfactory evaluation.

Stage 2: Application for Registration to MDA

For the purpose of registering a medical device-drug combination, applicant shall submit an application to MDA via the MeDC@St system with the following documents:

i. Endorsement letter issued by NPRA
ii. Data on medical device in accordance to guideline MDA/GL/MD-01 on How to Apply for Medical Device Registration under Medical Device Act 2012 (Act 737)

MDA shall register the Medical Device-Drug combination product and issue a medical device registration certificate upon approval.

3.0 DOSSIER REQUIREMENT FOR COMBINATION PRODUCT

The following dossier shall be submitted by the applicant for the purpose of registering combination product:

Table 1: Dossier Requirement for Combination Product

	Dossier Requirement for Drug Component	**Dossier Requirement for Medical Device Component**
Drug-Medical Device Combination Product	Refer to DRGD, Appendix 1: Requirements for Product Registration	Refer to Appendix 1: Ancillary Medical Device Dossier Requirement for Drug-Medical Device Combination Product
Medical Device-Drug Combination Product	Refer to Appendix 2: Ancillary Drug Dossier Requirement for Medical Device-Drug Combination Product	Refer to MDA/GD-04: Common Submission Dossier Template First Edition March 2014

4.0 TIMELINE FOR REGISTRATION OF COMBINATION PRODUCT

The following table specifies the duration (counted in working days upon receipt of complete application) that are required to perform product/ancillary dossier evaluation by each respective agency. Due to the nature of combination product which requires evaluation effort from both the Primary Agency and Secondary Agency, applicants are kindly advised to be vigilant on the overall timeframe required for combination product registration.

<table>
<tr><th>Stage</th><th>Drug-Medical Device Combination Product</th><th>Medical Device-Drug Combination Product</th></tr>
<tr><td>Stage 1</td><td>Evaluation timeline by MDA:<table><tr><th>Category</th><th>Duration (days)</th></tr><tr><td>Drug-Medical Device Combination Product <u>WITH</u> Approval from Reference Countries*</td><td>90</td></tr><tr><td>Drug-Medical Device Combination Product <u>WITHOUT</u> Approval from Reference Countries*</td><td>180</td></tr></table></td><td>Evaluation timeline by NPRA:<table><tr><th>Category</th><th>Duration (days)</th></tr><tr><td>New Chemical Entity</td><td>245</td></tr><tr><td>Biologic Component</td><td>245</td></tr><tr><td>Generics (Scheduled Poison)</td><td>90</td></tr><tr><td>Generics (Non-Scheduled Poison)</td><td>90</td></tr></table></td></tr>
<tr><td>Stage 2</td><td>Evaluation timeline by NPRA:<table><tr><th>Category</th><th>Duration (days)</th></tr><tr><td>New Drug Products</td><td>245</td></tr><tr><td>Biologics</td><td>245</td></tr><tr><td>Generics (Scheduled Poison)</td><td>210</td></tr><tr><td>Generics (Non-Scheduled Poison)</td><td>210</td></tr></table></td><td>Evaluation timeline by MDA:<table><tr><th>Class of Medical Device</th><th>Duration (days)</th></tr><tr><td>A</td><td>30</td></tr><tr><td>B</td><td>100</td></tr><tr><td>C</td><td>180</td></tr><tr><td>D</td><td>220</td></tr></table></td></tr>
</table>

**Refer Appendix 1: Ancillary Medical Device Dossier Requirement for Drug-Medical Device Combination Product*

5.0 FEES FOR REGISTRATION OF COMBINATION PRODUCT

Every application for registration shall be accompanied with a fee imposed by the respective agencies as specified in the table in Section 5.1 and 5.2.

Any payment made shall **NOT** be **REFUNDABLE** once the application has been submitted and payment confirmed.

Applications without the correct fees will not be processed.

5.1 FEES IMPOSED BY NPRA

Under the CDCR 1984, Regulation 8(3): The Authority may charge any applicant such costs as it may incur for the purpose of carrying out any evaluation or investigation prior to the registration of any product.

No.	Category of Product	* Processing Fees	Analysis Fees	Total Fees
Drug-Medical Device Combination Product				
1.	Pharmaceutical a. New Drug Products b. Biologics	RM 1,000.00	Single active ingredient : RM 3,000.00	RM 4,000.00
			Two or more active ingredients : RM 4,000.00	RM 5,000.00
2.	Pharmaceutical a. Generic (Scheduled Poison) b. Generic (Non-Scheduled Poison)	RM 1,000.00	Single active ingredient : RM 1,200.00	RM 2,200.00
			Two or more active ingredients: RM 2,000.00	RM 3,000.00

** As stipulated in the CDCR 1984, Regulation 8.*

Fees imposed for medical device-drug combination product:

Category of ancillary drug component	**Processing Fees**
1. New Chemical Entity 2. Biologic Component 3. Generics (Scheduled Poison) 4. Generics(Non-Scheduled Poison)	RM 1,000.00

5.2 FEES IMPOSED BY MDA

Application shall be accompanied with fees as specified by MDA. The fees stipulated below are per application basis.

Medical Device-Drug Combination Product (RM)		**Drug-Medical Device Combination Product (RM)**	
Application Fee	Registration Fee	Drug-Medical Device Combination Product **WITH** Approval from Reference Countries*	Drug-Medical Device Combination Product **WITHOUT** Approval from Reference Countries*
750	5000	300	600
Mode of Payment: Bank Draft/FPX		Mode of Payment: Bank Draft	

**Refer Appendix 1: Ancillary Medical Device Dossier Requirement for Drug-Medical Device Combination Product*

The application with a bank draft payable to "**KUMPULAN WANG PIHAK BERKUASA PERANTI PERUBATAN**" should be submitted to:

Chief Executive
Medical Device Authority (MDA)
Ministry of Health Malaysia
Level 6, Prima 9, Prima Avenue II
Blok 3547, Persiaran APEC
63000 Cyberjaya, Selangor
(Attn: Management and Service Unit)

Note: Information on reference number and phone number of the applicant must be written at the back of the bank draft, not in the table section. Kindly print invoice / payment advice along with the bank draft according to the category. The payment of different category shall be made separately.

6.0 CHANGES/VARIATION TO PARTICULARS OF A REGISTERED COMBINATION PRODUCT



Figure 2 : Flowchart Of Variation/Change Notification Process Of Combination Products

6.1 CHANGES/VARIATION TO PARTICULARS OF A REGISTERED DRUG-MEDICAL DEVICE COMBINATION PRODUCT

Application for changes to particulars of drug component for a registered Drug-Medical Device combination product shall be required to comply with Section 5.2: Amendments to Particulars of a Registered Product of DRGD.

Application for changes to particulars of ancillary medical device component for a registered drug-medical device combination product shall be submitted to MDA manually according to Appendix 6 along with:

a. Appendix 4: Notification Letter of Ancillary Component for Variation/Change Notification of Combination Product
b. Previous endorsement letter(s) issued by MDA

Approval letter issued by MDA shall then be required to be sent to NPRA for notification.

Note:

i. Application for changes to particulars of ancillary medical device component is not mandatory for low risk ancillary medical device components
ii. Ancillary medical devices that have already obtain prior registration approval with MDA; and subsequently approved of their change notification application with MDA **SHALL not be required** to proceed with this requirement.

6.2 CHANGES/VARIATION TO PARTICULARS OF A REGISTERED MEDICAL DEVICE-DRUG COMBINATION PRODUCT

Application for changes to particulars of medical device component for a registered medical device-drug combination product shall be required to comply to the Guidance Document of Change Notification to Registered Medical Device.

Application for changes to particulars of ancillary drug component for a registered medical device-drug combination product shall be submitted to NPRA manually according to the requirements in variation guidelines by NPRA with Appendix 4: Application Form for Approval Letter of Change/ Variation Application for Ancillary Components for Combination Products

NPRA shall issue an approval letter upon satisfactory evaluation.

APPENDIX 1: ANCILLARY MEDICAL DEVICE DOSSIER REQUIREMENT FOR DRUG-MEDICAL DEVICE COMBINATION PRODUCT

Documentation requirements shall be based on availability of regulatory approval or clearance as outlined in **Table 2** from the following countries/jurisdiction:

Table 2: Recognised regulatory agencies approval / clearance

Recognised Regulatory Authority	**Approval Type**
Therapeutic Goods Administration (TGA), Australia	TGA Marketing Authorization Approval (as medicinal product)
Health Canada, Canada	Drug Identification Number (DIN)
European Medicines Agency (EMA) or Other Competent Authorities from EU Member Countries European Union (EU)	Marketing Authorization and Marketing Authorization Number Annex II Section 3 or Annex V of MDD (for Class IIA) Annex II Section 3 or Annex III coupled with Annex V of MDD (for Class IIB) Annex II Section 3 and 4 of MDD (for Class III) Annex II Section 3 and 4 of AIMDD (for active implantable medical device) EC Declaration of Conformity Article 117 opinion report issued by a Notified Body
Pharmaceuticals and Medical Devices Agency (PMDA), Japan	Manufacturing/Marketing Approval Certificate (as medicinal product)
Food and Drug Administration (FDA) USA	Marketing Authorization and National Drug Code (NDC) USFDA 510 (k) clearance letter USFDA Pre-Market Approval (PMA) Letter
Medical Device Authority, Malaysia	Medical Device Registration Certificate and Number

Combination Product which:

i. HAS already obtained regulatory clearance as specified in **Table 2** is entitled for abridged documentation requirements (documentation proof of regulatory clearance must be enclosed together along with the dossier).

ii. HAS NOT obtained regulatory clearance as specified in **Table 2** is required to submit all of documentation requirements.

Table 3 detailed out about documentation requirements for ancillary medical device dossier. The information contained in the dossier should be supported by relevant supporting documents for example copies of labels, certificates and reports. Those documents must be legible and within its validity period. Refer **MDA/GD/0008 Common Submission Dossier Template (CSDT)** for further explanation on the elements stated below.

Table 3: Documentation requirements for ancillary medical device dossier

Ancillary Medical Device Dossier		**Drug-Medical Device Combination Product WITH Approval from Reference Countries**	**Drug-Medical Device Combination Product WITHOUT Approval from Reference Countries**
i.	Overview of the Medical Device which covers an introductory descriptive information on the medical device, the intended uses and indications for use of the medical device, principles of operation or mode of action	/	/
ii.	Labelled pictorial representation for the Medical Device (e.g. diagrams, photographs and drawings)	/	/
iii.	Description of the accessories (other medical devices and other products that are not medical devices, which are intended to be used in combination with the medical device)	/	/
iv.	Instruction of use (IFU) / Product Catalogue / Brochure including the procedures, methods, frequency, duration, quantity and preparation to be followed for safe use of the medical device	/	/

Ancillary Medical Device Dossier		**Drug-Medical Device Combination Product <u>WITH</u> Approval from Reference Countries**	**Drug-Medical Device Combination Product <u>WITHOUT</u> Approval from Reference Countries**
v.	Contraindications, Warnings, Precautions and Potential Adverse Effects related to the Medical Device	X	/
vi.	Materials to describe their physical properties	X	/
vii.	3 years commercial marketing history* which covers the list of countries where the medical device AND/OR combination product is marketed, list of regulatory approval or marketing clearance obtained including the registration status and status of any pending request for market clearance. *Note: For combination product or medical device with reference agencies approval or marketing clearance as specified in **Table 2**, documentation proof of regulatory approval or clearance AND declaration of no safety issues associated with the combination product globally are sufficient.	/*	/
viii.	3 years summary of reportable adverse events and field corrective actions (FCAs) related to the medical device	/	/
ix.	Summary of design verification and validation documents Pre-clinical studies: This section should summarize or reference or contain report and/or certification and/or declaration of; a. Biocompatibility test conducted on materials used in a medical device; b. Pre-clinical physical tests conducted on the medical device; c. Pre-clinical animal studies to support the probability of effectiveness in humans.	/**	/

Ancillary Medical Device Dossier		**Drug-Medical Device Combination Product <u>WITH</u> Approval from Reference Countries**	**Drug-Medical Device Combination Product <u>WITHOUT</u> Approval from Reference Countries**
	Clinical Evidence: This section should indicate how any applicable requirements of the Essential Principles for clinical evaluation of the device have been met. Where applicable, this evaluation may take the form of d. a systematic review of existing bibliography, e. clinical experience with the same or similar devices, or f. clinical investigation. **Note: For Drug-Medical Device Combination Product <u>WITH</u> Approval from Reference Countries, the following shall be provided: • Clinical evidence/data addressing relevant safety and performance-related to the medical device; AND/OR • Has obtained regulatory agencies approval or clearance as in **Table 2** (only applicable for co-packaged medical device)		
x.	Risk analysis should summarize or reference or contain information on risk analysis conducted for the medical device is to be provided in the form of a risk management report.	X	/
xi.	Manufacturing information should summarize or reference or contain documentation related to the manufacturing processes, including quality assurance measures. It should be provided in the form of a list of resources and activities that transform inputs into the desired output. Relevant Quality Management System (QMS) for the medical device AND/OR combination product (e.g Good Manufacturing Practice or ISO13485) shall be provided.	/	/

Ancillary Medical Device Dossier	**Drug-Medical Device Combination Product <u>WITH</u> Approval from Reference Countries**	**Drug-Medical Device Combination Product <u>WITHOUT</u> Approval from Reference Countries**
xii. Relevant essential principles and rule used to demonstrate conformity: The Essential Principles that are applicable to the device and the general rule or method used to demonstrate conformity to each applicable Essential Principle.	/	/

Explanatory Notes: [/] – Required; [X] – Not required

APPENDIX 2: ANCILLARY DRUG DOSSIER REQUIREMENT FOR MEDICAL DEVICE-DRUG COMBINATION PRODUCT

Part I: General Information	
No.	**Section A: Combination Product Particulars**
1.	Combination Product Name
2.	Name & Strength of Active Substance and Excipient
3.	Dosage Form
4.	Product Description
5.	Pharmacodynamics
6.	Pharmacokinetics
7.	Indication
8.	Recommended Dose
9.	Route of Administration/Mode of Delivery
10.	Contraindication
11.	Warning and Precautions
12.	Interaction with Other Medicaments (If Applicable)
13.	Pregnancy and Lactation (If Applicable)
14.	Side Effects (If Applicable)
15.	Symptoms and Treatment of Overdose (If Applicable)
16.	Storage Condition (If Applicable)
17.	Shelf Life (If Applicable)
18.	Declaration of human/ animal origin (If Applicable)
No.	**Section B: Drug Product Formula**
1.	Batch Manufacturing Formula
No.	**Section C: Mock-up Label**
1.	General Labelling Requirement “Controlled Medicine/ Ubat Terkawal” (for Scheduled poison only unless exempted)
2.	Specific labelling requirement as stated in DRGD (if applicable)

PART II: QUALITY OF DRUG COMPONENT	
1.	Information on Development Studies
2.	Manufacturing Process and Process Controls
3.	Control of Excipients (if applicable)
	a. Specifications of Excipient
	b. Justification of Specifications (if applicable)
4.	Control of Drug Substances
	a) Nomenclature, Structure of Drug Substance, General Properties
	b) Manufacturer Name and Address
	c) Description of Manufacturing Process and Process Controls (only for biologic component)
	d) Controls of Materials (only for biologic component)
	e) Controls of Critical Steps and Intermediates (only for biologic component)
	f) Process Validation and/or Evaluation (only for biologic component)
	g) Manufacturing Process Development (only for biologic component)
	h) Elucidation of Structure and Characteristics(only for biologic component)
	i) Impurities (only for biologic component)
	j) Specifications
	k) Batch Analysis (only for biologic component)
	l) Certificate of Analysis for TWO batches
	m) Justification of Specifications (only for biologic component)
	n) Reference Standards or Materials (only for biologic component)
	o) Container Closure System (only for biologic component)
	p) Stability (only for biologic component)
PART III: NON CLINICAL DOCUMENT (Applicable only to New Chemical Entity and Biologic Component)	
	Section A: Table of Contents
No.	**Section B: Nonclinical Overview**
1.	Overview of the Nonclinical Testing Strategy
2.	Pharmacology
3.	Pharmacokinetics

4.	Toxicology
5.	Other Non-Clinical Study
6.	Integrated Overview & Conclusions
7.	List of Literature Citations
No.	**Section C: Nonclinical Written and Tabulated Summaries**
No.	**Section D: Nonclinical Study Reports**
No.	**Section E: List of Key Literature References**
PART IV: CLINICAL DOCUMENT (Applicable only to category New Chemical Entity and Biologic Component)	
No.	**Section A: Table of Contents**
No.	**Section B: Clinical Overview**
1.	Product Development Rationale
2.	Overview of Biopharmaceutics
3.	Overview of Clinical Pharmacology
4.	Overview of Efficacy
5.	Overview of Safety
6.	Benefits & Risks Conclusions
No.	**Section C: Clinical Summary**
1.	Summary of Biopharmaceuticals Studies and Associated Analytical Methods
2.	Summary of Clinical Pharmacology Studies
3.	Summary of Clinical Efficacy
4.	Summary of Clinical Safety
5.	Synopses of Individual Studies
No.	**Section D: Tabular Listing of all Clinical Studies**
No.	**Section E: Clinical Study Reports**

APPENDIX 3: APPLICATION FORM FOR ENDORSEMENT LETTER OF ANCILLARY COMPONENT FOR THE REGISTRATION OF COMBINATION PRODUCT

KEMENTERIAN KESIHATAN MALAYSIA
Ministry of Health Malaysia
Portal: www.moh.gov.my
Email: kkm@moh.gov.my

APPLICATION FORM FOR ENDORSEMENT LETTER OF ANCILLARY COMPONENT FOR THE REGISTRATION OF COMBINATION PRODUCT

CHECKLIST FOR SUBMISSION

DOCUMENTS	COMBINATION PRODUCT		Please tick if the document is attached
	DRUG-MEDICAL DEVICE	MEDICAL DEVICE-DRUG	
Ancillary Medical Device Dossier *(Appendix 2 of Guideline for Registration of Drug-Medical Device and Medical Device-Drug Combination Products)*	/	X	
Ancillary Drug Dossier *(Appendix 3 of Guideline For Registration of Drug-Medical Device and Medical Device-Drug Combination Products)*	X	/	

Explanatory Notes: [/] – Required; [X] – Not required

The form and supporting documents can be sent either via email or post hardcopy to:

For Ancillary Medical Device Components	**For Ancillary Drug Components**
Chief Executive, Medical Device Authority, Level 6, Prima 9, Prima Avenue II, Blok 3547, Persiaran APEC, 63000 Cyberjaya, Selangor. E-mail: combination.product@mda.gov.my	Secretary, Drug Control Authority, National Pharmaceutical Regulatory Agency, Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor. E-mail: helpdesk@npra.gov.my

Please complete all information requested. *All fields are mandatory unless stated otherwise.*	
1. ***APPLICANT DETAILS**	
Name of Applicant:	
NRIC No. / Passport:	Designation:
Name & Address of Company:	
ROC No.:	
City:	State:
Telephone No.:	Fax No.:
Email Address:	
Role of Applicant:	
☐	Product Registration Holder
☐	Manufacturer *Establishment License No.:*
☐	Authorized Representative *Establishment License No.:*
☐	Others (*please specify*):
**Note:The application for obtaining endorsement letter and combination product registration must be submitted by the same applicant*	
2. COMBINATION PRODUCT DETAILS *Please provide product packaging label, product catalogue and product insert*	
☐	Drug-Medical Device
☐	Medical Device-Drug
Product Name:	Manufacturer's Name:
Brand/Model:	
Product Description:	
Intended Use/Indication:	

3. ANCILLARY MEDICAL DEVICE DETAILS

(Only applicable to Drug-Medical Device Combination Product)

Name of Medical Device	
Description of Medical Device	
Intended Use of Medical Device	
Brand/Model of Medical Device	
Name & Address of Manufacturer for the Medical Device	

Table 1: List of Configurations

No.	Name of device, accessories, constituent-components, or articles as per product label:	Model	Device Description

Note: If more than one (1) single medical device, please fill out in a separate sheet.

4. ANCILLARY COMPONENT DETAILS

Please provide details of the ancillary component according to the following:

- Ancillary Medical Device Dossier (refer Appendix 2 of Guideline For Registration of Drug-Medical Device and Medical Device-Drug Combination Products)
- Ancillary Drug Dossier (refer Appendix 3 of Guideline For Registration of Drug-Medical Device and Medical Device-Drug Combination Products)

5. ATTESTATION & DECLARATION

I, <Name of applicant>, ID <NRIC No. / Passport >, on behalf of <Name of company>
the product holder/manufacturer/authorize representative of this ancillary component, hereby declare that :

(tick where applicable)

☐ **Drug-Medical Device**:

i. This/these ancillary medical device(s) component is/are according to the definition of medical device set out in Section 2, Medical Device Act 2012 (Act 737).

☐ **Medical Device-Drug**:

i. This ancillary drug component is according to the definition of drug set out in Control of Drugs and Cosmetics Regulations 1984 which is promulgated under Sales of Drugs Act1952.

I hereby attest that the information and attachment provided on this form are accurate, correct, complete and current to this date.

Signature:

Applicant's Name:

Designation :

Date :

Company stamp :

APPENDIX 4: APPLICATION FORM FOR APPROVAL LETTER OF CHANGE/VARIATION APPLICATION FOR ANCILLARY COMPONENTS FOR COMBINATION PRODUCTS

KEMENTERIAN KESIHATAN MALAYSIA
Ministry of Health Malaysia
Portal: www.moh.gov.myEmail: kkm@moh.gov.my

APPLICATION FORM FOR APPROVAL LETTER OF CHANGE/VARIATION APPLICATION FOR ANCILLARY COMPONENTS FOR COMBINATION PRODUCTS

CHECKLIST FOR SUBMISSION

DOCUMENTS	COMBINATION PRODUCT		Please tick if the document is attached
	DRUG-MEDICAL DEVICE	MEDICAL DEVICE-DRUG	
Documentations as per in Guidance Document for Change Notification by MDA	/	X	
Documentations as per in Variation Guidelines by NPRA	X	/	
Previous Endorsement Letter(s) Issued by MDA	/	X	
Previous Endorsement Letter(s) Issued by NPRA	X	/	

Explanatory Notes: [/] – Required; [X] – Not required

The form and supporting documents can be sent either via email or post hardcopy to:

For Ancillary Medical Device Components	**For Ancillary Drug Components**
Chief Executive, Medical Device Authority, Level 6, Prima 9, Prima Avenue II, Blok 3547, Persiaran APEC, 63000 Cyberjaya, Selangor. E-mail: combination.product@mda.gov.my	Secretary, Drug Control Authority, National Pharmaceutical Regulatory Agency, Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor. E-mail: helpdesk@npra.gov.my

Please complete all information requested. *All fields are mandatory unless stated otherwise.*	
1. ***APPLICANT DETAILS**	
Name of Applicant:	
NRIC No. / Passport:	Designation:
Name & Address of Company:	
ROC No.:	
City:	State:
Telephone No.:	Fax No.:
Email Address:	
Role of Applicant:	
☐	Product Registration Holder
☐	Manufacturer *Establishment License No.:*
☐	Authorized Representative *Establishment License No.:*
☐	Others (*please specify*):
**Note:The application for obtaining endorsement letter and combination product registration must be submitted by the same applicant*	
2. COMBINATION PRODUCT DETAILS	
☐	Drug-Medical Device (Registration Number :)
☐	Medical Device-Drug (Registration Number :)
☐	Previous Endorsement Letter(s) Reference No :
Product Name:	Manufacturer's Name:
Brand/Model:	
Product Description:	
Intended Use/Indication:	

3. ANCILLARY MEDICAL DEVICE DETAILS
(Only applicable to Drug-Medical Device Combination Product)

Name of Medical Device	
Description of Medical Device	
Intended Use of Medical Device	
Brand/Model of Medical Device	
Name & Address of Manufacturer for the Medical Device	

Table 1: List of configurations

No.	Name of device, accessories, constituent-components, or articles as per product label:	Model	Device Description

Note: If more than one (1) single medical device, please fill out in a separate sheet.

4. ATTESTATION & DECLARATION

I, <Name of applicant>, ID <NRIC No. / Passport >, on behalf of <Name of company>
the product holder/manufacturer/authorize representative of this ancillary component,
hereby declare that :

(tick where applicable)

☐ **Drug-Medical Device**:

i. This/these ancillary medical device(s) component is/are according to the definition of medical device set out in Section 2, Medical Device Act 2012 (Act 737).

☐ **Medical Device-Drug**:

i. This ancillary drug component is according to the definition of drug set out in Control of Drugs and Cosmetics Regulations 1984 which is promulgated under Sales of Drugs Act1952.

I hereby attest that the information and attachment provided on this form are accurate, correct, complete and current to this date.

Signature:

Applicant's Name:

Designation :

Date :

Company stamp :

APPENDIX 5: ENDORSEMENT LETTER APPLICATION FLOW CHART FOR ANCILLARY MEDICAL DEVICE COMPONENT

Figure 5: Endorsement Letter Application Flow Chart for Ancillary Medical Device Component



[1] Refer Appendix 3 guideline registration of drug-medical device and medical device-drug combination products.

Figure 6: Application for Medical Device-Drug Combination Product Flow Chart



[1] Refer Appendix 3 guideline registration of drug-medical device and medical device-drug combination products.

[2] Refer to MDA/GL/MD-01: How to Apply for the Medical Device Registration under Act 737

APPENDIX 6: CHANGE TO ANCILLARY MEDICAL DEVICE COMPONENTS

6.1 CATEGORIES OF CHANGES

Change to ancillary medical device components may be categorized into the following categories:

a) **Technical Changes** – major changes to particular of ancillary medical device components

b) **Administrative Changes** – minor changes to particular of ancillary medical device components

c) Any other changes that affect their safety and performance requires new endorsement letter application

MDA/GD/0020 - Change Notification for Registered Medical Device, a Guidance Document published by MDA can be referred for clarification of the terminologies used in this Appendix

The following Tables (Table 4 and Table 5) outline the guiding principles for identification of various types of change to ancillary medical device components.

(Note: Any other change that occurs to the ancillary medical device components that does not affect their safety and performance; AND not outlined in these Tables does not trigger the need for change notification)

The guiding principles for identification of Technical Changes of various types of change to medical devices are presented in Table 4. Applicant are required to provide the documents for each change that occur to the ancillary medical device components as outlined in the table.

Table 4: Technical Changes

Types of change	Documents to be submitted**
4.1 Change in manufacturing facility, process and quality management system (QMS)	
(a) All changes to manufacturing and/or sterilisation facilities with no changes to the manufacturing and/or sterilisation processes. *Example:* *Change of manufacturing site.*	i) Revised QMS certificate(s) (if applicable); ii) Medical Device labelling stating changes for each amended section (if applicable); iii) Declaration that there is no change to manufacturing and sterilisation process; iv) Sterilisation validation report.
(b) All changes to manufacturing processes (including changes made to outsourced processes) that result in a change in specifications of a medical device. *Example:* *Change in the equipment used for cutting the result in the change in length of sutures.* *Moulding or cutting manufacturing process.*	i) Revised QMS certificate(s) (if applicable); ii) Summary of new manufacturing process; iii) Validation report covering new processes; iv) Pre-clinical studies (if applicable); v) Software validation report (for software); vi) Clinical safety report (for operating principles and design characteristics change) (if applicable); vii) Risk analysis.
(c) All changes to sterilisation processes (including changes made to outsourced processes). *Example:* *Change in moist heat sterilisation parameters, or change in sterilisation method from ethylene oxide to gamma radiation, or change from batch release to parametric release.*	i) Sterilisation technique (certificate); ii) Medical Device labelling stating changes for each amended section (if applicable); iii) Sterilisation validation report (including the sterilisation protocol, sterilisation standards applied, sterility assurance level, sterilisation revalidation report); iv) QMS certificate(s).

Types of change	Documents to be submitted**
4.2 Changes in design or specifications of a medical device	
(a) All changes to the control mechanisms, operating principles and/or design characteristics of a medical device. *Example:* *Change from a quantitative assay to a qualitative assay.* *Addition of a footswitch to an X-ray system that previously do not operate via a footswitch mechanism.*	i) Revised QMS certificate(s) (if applicable); ii) Pre-clinical studies; iii) Risk analysis; iv) Clinical studies (if applicable); v) Software validation report (for software, if applicable); vi) Detailed summary of software changes (for software, if applicable).
(b) Changes that only involves a design change that does not affect the safety or performance of the medical device (e.g. changes that improve the medical device ergonomics, aesthetic modification of the medical device).	i) Revised QMS certificate(s) (if applicable); ii) Risk analysis; iii) Usability testing report (if applicable).
(c) All changes in specifications (including shelf life and stability) of a medical device.	i) Revised QMS certificate(s) (if applicable); ii) Pre-clinical studies (if applicable); iii) Clinical safety report (if applicable); iv) Risk analysis; v) Software validation report (for software, if applicable); vi) Detailed summary of software changes (for software, if applicable).
(d) Change to software that affect safety and performance of the device such that the treatment or diagnosis of the patient is altered. *Example:* *Upgrade of software version changes the performance characteristics like*	i) Revised QMS certificate(s) (if applicable); ii) Risk analysis; iii) Software validation report; iv) Detailed summary of software changes.

Types of change	Documents to be submitted**
specificity or sensitivity of the diagnostic medical device.	
4.3 Changes to materials in a general medical device	
(a) All changes to biological materials that involve a change in type, source, processing and/or supplier of cells, tissues and/or derivatives of animal, human, microbial or recombinant origin without a change in the intended purpose of the biological material. *Example:* *Change in source of hyaluronic acid from Streptococcus zooepidemicus to Streptococcus equi.*	i) Revised QMS certificate(s) (if applicable); ii) Pre-clinical studies, including biological safety data; iii) Clinical safety report (if applicable); iv) Information of sources/donors; v) Risk analysis;
(b) All changes to materials or material formulation (of non-biological origin), including changes to medical device coating or surface modification techniques, that involve materials that make direct/indirect contact with body tissues and fluids, or are absorbed by the body. *Example:* *Replacement of catheter surface coating from PEBA to PEEK.*	i) Revised QMS certificate(s) (if applicable); ii) List of materials making direct/ indirect contact with human body; iii) Pre-clinical studies; iv) Clinical safety report (if applicable); v) Risk analysis.
(c) All changes to materials that are used for shielding in medical devices emitting ionising radiation. *Example:* *Change in shielding material of X-ray system from lead to tungsten.*	i) Revised QMS certificate(s) (if applicable); ii) Information on radiation source; iii) Information on materials for shielding of radiation; iv) Radiation safety test/test report; v) Risk analysis.
(d) All changes to the radiation source (e.g. radioisotopes).	i) Revised QMS certificate(s) (if applicable); ii) Information on radiation source; iii) Radiation safety test/test report;

Types of change	**Documents to be submitted****
	iv) Risk analysis.
4.4 Changes to materials in an in-vitro diagnostic (IVD) medical device	
(a) All changes to the radiation source (e.g. radioisotopes in radioimmunoassay).	i) Revised QMS certificate(s) (if applicable); ii) Pre-clinical performance evaluation data; iii) Clinical performance evaluation data; iv) Information on source of material; v) Radiation safety test/test report; vi) Risk analysis.
4.5 Changes to ancillary medical devices information	
(a) If within the medical device list of configurations, the change only— i) involves the addition or reduction of new medical devices of the same design OR ii) involves addition of a new medical device with design change that does not affect the safety or performance of the medical device (e.g. changes that improve medical device ergonomics, aesthetic modification of the medical device).	i) Justification for addition of medical device(s) to be grouped within the medical device group; ii) List of configurations of medical devices; iii) Regulatory approval documents from the recognized countries (if applicable); iv) Medical Device information; v) Pre-clinical studies (where applicable); vi) Software validation report (for software, if applicable); vii) Manufacturing information (if applicable).
c) All changes to the medical device name and/or medical device identifier.	i) Declaration from manufacturer to state that there is no change to medical device in all aspects, including intended use, technical specifications; ii) List of configurations of medical device;
The Authority may, in writing, at any time after the receipt of an application, request the applicant to give to the Authority within 30 days, particulars or document on the application or sample of the medical device. If any additional information, particulars or document, or sample of the medical device required is not given by the applicant within the period specified in the request or any extension of time granted by the Authority, the application shall be deemed to be withdrawn and shall not be further proceeded with, but without affecting the right of the applicant to make fresh application.	

The guiding principles for identification of Administrative Changes of various types of change to medical devices are presented in Table 5. Applicant are required to provide the documents for each change that occur to the ancillary medical device components as outlined in the table.

Table 5: Administrative Changes

Types of change	Documents to be submitted**
5.1 Change in manufacturing facility, process and quality management system (QMS)	
(a) All changes to certificates for manufacturing and sterilization facilities that - i) involves an update of certificate QMS validity date only OR; ii) change in scope of the QMS certification which affect the medical device (that is not due to safety, and/or performance of the medical device) OR; iii) involves a cancellation of QMS scope on the certificate for any of the multiple existing manufacturing facilities that is related to the medical device (that is not due to safety, and/or performance of the medical device)	Valid QMS certificate and report.
5.2 Changes in design or specifications of a medical device	
All changes in software related to design or specifications of a medical device requires new endorsement application, (a) Unless the change only involves a change to software version number that does not affect safety or performance of the medical device, such as—	i) Software validation report. ii) Detailed summary of software changes. The change notification for this item may be consolidated for a maximum period of 6 months.

Types of change	**Documents to be submitted****
i) software changes solely to correct an inadvertent software error which does not add new functions, does not pose any safety risk and is intended to bring the system to its original specification; ii) software changes which augment interfacing to other non-medical peripherals such as printers or VDUs and which has no diagnostic or therapeutic function; or iii) software changes which only modify the appearance of the user interface with no risk to diagnostic or therapeutic function of the medical device.	
5.3 Changes to ancillary medical devices information	
b) All deletions of a medical device from medical device listing *Example:* *The change only involves the reduction in the number of medical devices in the grouping due to obsolescence and not due to safety or performance considerations.*	i) Justification for deletion of medical device(s) to be grouped within the medical device; ii) Declaration from manufacturer to state that there is no change to medical device in all aspects, including intended use, technical specifications; iii) List of configurations of medical devices
c) A change in regulatory status on rejection or withdrawal in any recognized countries for any medical device.	i) Existing regulatory approval; ii) Documents from relevant regulatory authorities citing reason for the change in regulatory status; iii) Reason for company to withdraw from regulatory authorities (if applicable).

Types of change	Documents to be submitted**
The Authority may, in writing, at any time after the receipt of an application, request the applicant to give to the Authority within 30 days, particulars or document on the application or sample of the medical device. If any additional information, particulars or document, or sample of the medical device required is not given by the applicant within the period specified in the request or any extension of time granted by the Authority, the application shall be deemed to be withdrawn and shall not be further proceeded with, but without affecting the right of the applicant to make fresh application.	

6.2 SUMMARY TABLE OF CHANGES

The following provides guidelines on completing the Summary Table of Change Notification.

(a) This summary table is to be completed and submitted for all change applications.

(b) List the proposed changes, according to the "category of change", to the registered medical device(s) in the summary table below. All applicable types of changes are to be included; any change not specified in this table will not be included for the change notification.

(c) Information to be included in the table is explained below:

i) **Type of changes:** Please state clearly the **type of change**, **category of change** and **reference number of the endorsement letter of ancillary medical device**

- With reference to the 'type of changes' categories in 6.1, highlight the type of change proposed.
- Specify the **reference number of the endorsement letter of ancillary medical device** included in this change
- ***NOTE*** *All applicable types of changes are to be included. If the types of change proposed affects/results in another type of change, all types of changes shall be included. For example, change in material of medical device and change (update) of labelling often occur together.*

ii) **Present:** Please state clearly the current scope and aspects of the medical device to be changed.

iii) **Proposed:** Please state clearly the proposed scope and aspects of change.

iv) **Reason for change:** Please state clearly the rationale for the proposed scope and aspects of change.

v) **Status of proposed change in recognized countries:** Please state the reference agency status (approved/authorized for marketing) for these proposed changes.

(a) Type of changes	(b) Present	(c) Proposed	(d) Reason for change	(e) Status of proposed change in recognised countries
Type of change: *e.g. Change in material: Delivery tube material changed from polyvinyl chloride(PVC) to silicone* **Category of change:**	*Delivery tube material: polyvinylchloride (PVC)* **Endorsement Letter Reference No:** **List of medical device** i) ii) iii)	*Delivery tube material: silicone*	*Improve patient safety by changing to DEHP-free tubing material*	*Australia TGA – pending* *EU Notified Body – approved/authorised for marketing* *Health Canada – not supplied* *US FDA – not supplied* *Japan MHLW – not supplied*
Type of change: *e.g. Change in manufacturing facility* **Category of change:**	*Name and address of current manufacturing facility A* **Endorsement Letter Reference No:** **List of medical device** i) ii) iii)	*Name and address of new manufacturing facility B*	*Reason for to move manufacturing activities from facility A to facility B*	*Australia TGA – pending* *EU Notified Body – approved/authorised for marketing* *Health Canada – not supplied* *US FDA – not supplied* *Japan MHLW – not supplied*

6.3 FEES IMPOSED BY MDA

Application shall be accompanied with fees as specified by MDA. The fees stipulated below are per application basis. Mode of payment: Bank Draft

No	Type of Change	Fee (RM)
1.	Technical Change	150
2.	Administrative Change	30

The application with a bank draft payable to "**KUMPULAN WANG PIHAK BERKUASA PERANTI PERUBATAN**" should be submitted to:

Chief Executive
Medical Device Authority (MDA)
Ministry of Health Malaysia
Level 6, Prima 9, Prima Avenue II
Blok 3547, Persiaran APEC
63000 Cyberjaya, Selangor
(Attn: Management and Service Unit)

Note: Information on reference number and phone number of the applicant must be written at the back of the bank draft, not in the table section. Kindly print invoice / payment advice along with the bank draft according to the category. The payment of different category shall be made separately.

6.4 EVALUATION TIMELINE

The following table specifies the evaluation duration (counted in working days upon receipt of complete application) for the application of endorsement letter of Ancillary Medical Device Component.

No	Type of Change	Evaluation Timeline (working days)
1.	Technical Change	60
2.	Administrative Change	30

APPENDIX 7: LIST OF RELEVANT REFERENCES

A) MEDICAL DEVICE AUTHORITY (MDA)

7.1 Legislation

1. Medical Device Act 2012 (Act 737)
2. Medical Device Regulations 2012

7.2 Circular Letter

1. **Circular Letter PBPP No.2/2014:** Conformity Assessment Procedures For Medical Device Approved By Recognized Countries

2. **Circular Letter PBPP No.3/2017:** Implementation And Enforcement Of Guideline For Registration Of Drug-Medical Device And Medical Device-Drug Combinations Products (Revision 1)

7.3 Guidance Document

1. **MDA/GL/MD-01 (Third Edition)**: How to Apply for the Medical Device Registration under Act 737
2. **MDA/GD/0005:** Product Grouping
3. **MDA/GD/0006:** Definition of Medical Device
4. **MDA/GD/0007:** The Essential Principles of Safety and Performance of Medical Devices
5. **MDA/GD/0008:** Common Submission Dossier Template (CSDT)
6. **MDA/GD/0009:** Rules of Classification for General Medical Devices
7. **MDA/GD/0020:** Change Notification for Registered Medical Device
8. **MDA/GD/0025:** Declaration of Conformity (DoC)
9. **MDA/GD/0026:** Requirements for Labelling of Medical Devices
10. **MDA/GD/0031:** Conformity Assessment for Medical Device

B) NATIONAL PHARMACEUTICAL REGULATORY AGENCY (NPRA)

7.4 Legislation

1. Poisons Act 1952
2. Sales of Drugs Act 1952 and Regulations
3. Control of Drugs and Cosmetic Regulations 1984 (CDCR 1984)
4. Dangerous Drugs Act 1952 (DDA 1952)

7.5 Directives & Circulars for Combination Products

1. **Circular Letter Bil.2/2015:** Keperluan Ahli Farmasi Berdaftar Sepenuh Masa untuk Mengetuai Bahagian Pengeluaran Premis Pengilang Produk Farmaseutikal, Radio Farmaseutikal dan Veterinar yang Berdaftar dengan Pihak Berkuasa Kawalan Dadah (PBKD) : Perlanjutan Tarikh Perlaksanaan.

2. **Directive Letter Bil.1/2016:** Arahan Pengarah Kanan Perkhidmatan Farmasi Bilangan 1 Tahun 2016 - Direktif Mengenai Keperluan Pemeriksaan Amalan Perkilangan Baik (APB) Luar Negara bagi Tujuan Pendaftaran / Pendaftaran Semula Produk Farmaseutikal Berdaftar dengan Pihak Berkuasa Kawalan

3. **Directive Letter Bil.11/2016:** Arahan Pengarah Kanan Perkhidmatan Farmasi Bil. 11 Tahun 2016 - Penerimaan Pengesahan Pematuhan APB Bagi Tujuan Pendaftaran Semula Produk Farmaseutikal Berdaftar

4. **Directive Letter Bil.4/2017:** Directives & Circulars for Combination Products

5. **Directive Letter Bil.7/2017:** Direktif Untuk Menguatkuasakan Penggunaan Guideline For Registration Of Drug-Medical Device And Medical Device-Drug Combination Products

6. **Directive Letter Bil. 7/2017:** Direktif untuk pendaftaran semula bersyarat bagi produk farmaseutikal berdaftar yang masih belum memenuhi keperluan data kajian stabiliti dalam zon IV B

7. **Pekeliling KKM.600-18/2/66Jld.3(35) :** Pekeliling Mengenai Pelaksanaan Produk Persediaan Parenteral Yang Telah Dikelaskan Sebagai Racun Di Bawah Akta Racun 1952

8. **Directive Letter Bil. 21/2017:** Direktif Berhubung Penggunaan Label Keselamatan Hologram Meditag

9. **Directive Letter Bil. 4/2017:** Lanjutan Tarikh Pelaksanaan Pemakaian Guideline For Registration Of Drug-Medical Device And Medical Device-Drug Combination Products

7.6 Guidance Document

1. **Drug Registration Guidance Document (DRGD) : Second Edition – September 2016, revised January 2019**

2. **Malaysian Pharmacovigilance Guidelines 2nd Edition- September 2016,**

3. **Malaysian Variation Guideline For Biologics (MVGB) : First Edition: January 2017**

4. **MALAYSIAN VARIATION GUIDELINE FOR PHARMACEUTICAL PRODUCTS (MVGP) : April 2013**